20-F: Aptorum Group Faces Going Concern Doubt Amid R&D Focus & Merger

Aptorum Group's latest annual report highlights a net loss, negative working capital, and substantial doubt about its ability to continue as a going concern, despite focusing on lead R&D projects and a proposed merger with DiamiR Biosciences.

Summary

• Reported a net loss of $1,376,430 for the fiscal year ended December 31, 2025, a decrease from $4,157,737 in 2024.
• Had negative working capital of $1,001,299 and an accumulated deficit of $73,792,798 as of December 31, 2025.
• The independent auditor expressed substantial doubt about the company's ability to continue as a going concern.
• The company is a clinical-stage biopharmaceutical firm focusing on oncology and infectious diseases, with lead projects ALS-4 and SACT-1.
• Paused the majority of R&D activities in 2025 to focus on a proposed all-stock merger with DiamiR Biosciences Corp.
• The merger, if consummated, would result in DiamiR stockholders owning approximately 70% and existing Aptorum shareholders approximately 30% of the combined company.
• DiamiR Biosciences is a molecular diagnostics company with over 50 issued patents, specializing in neurodegenerative diseases and cancer detection.
• Secured gross proceeds of $2,000,000 from a registered direct offering in October 2025 and $3,070,000 in January 2025.
• Extended a $3,000,000 secured convertible note with Jurchen Investment Corporation (a related party and largest shareholder) for an additional 12 months, bearing 6% interest per annum and convertible at $2.42 per share.
• Identified a material weakness in internal control over financial reporting due to a lack of dedicated resources for finance and accounting functions and U.S. GAAP financial statement preparation.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a low score due to the explicit 'going concern' warning from the auditor, significant accumulated deficit, and negative working capital, indicating severe financial distress. While there are positive R&D updates and capital raises, the fundamental financial stability is highly questionable, and the proposed merger is still subject to conditions.

Positives

• Net loss decreased significantly to $1,376,430 in FY 2025 from $4,157,737 in FY 2024.
• Completed Phase 1 clinical trial for ALS-4 with no serious adverse events observed.
• Received positive feedback from the US FDA on the overall development strategy for ALS-4, progressing towards IND submission for Phase 2 trials targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
• SACT-1 received Orphan Drug Designation from the US FDA in January 2022.
• Completed End of Phase 1 (EOP1) meeting for SACT-1 with the US FDA, with general agreement on CMC strategy and proposed Phase 1/2 trials plan.
• SACT-1 demonstrated statistically significant tumor shrinkage (up to 54.2%) in a neuroblastoma xenograft mouse model when combined with standard of care chemotherapy.
• The SACT-1 patent portfolio includes two granted US patents (US 11,166,952 B2 and US 11,571,422) expiring on November 27, 2040, and nine active national phase patent applications worldwide.
• Successfully raised $2,000,000 and $3,070,000 in gross proceeds from registered direct offerings in October 2025 and January 2025, respectively.
• Actively seeking strategic collaborators to provide financial support and clinical expertise for advancing lead therapeutic programs.
• The proposed merger with DiamiR Biosciences Corp. offers diversification into molecular diagnostics with over 50 issued patents.

Negatives

• Reported a net loss of $1,376,430 for the year ended December 31, 2025.
• Had negative working capital of $1,001,299 as of December 31, 2025.
• Accumulated deficit reached $73,792,798 as of December 31, 2025.
• The independent auditor expressed substantial doubt about the company's ability to continue as a going concern.
• R&D activities were largely paused in 2025 to focus on the DiamiR merger, potentially delaying progress on lead projects.
• Terminated clinic services and suspended non-lead R&D projects in Q2 2023, resulting in no revenue from healthcare services in 2024 and 2025.
• The merger agreement with YOOV Group Holding Limited was terminated in October 2024.
• An ongoing lawsuit filed by Karen Cheung alleges RICO violations, fraud, and other claims.
• Legal and professional fees increased to $1,062,346 in 2025 from $803,285 in 2024, primarily due to non-routine merger-related activities.
• Significant dependence on additional financing to fund operations and advance drug candidates, with no guarantee of availability or favorable terms.
• The Chief Executive Officer, Ian Huen, controls approximately 87% of the voting power, which may not always align with the interests of other shareholders.
• A material weakness in internal control over financial reporting was identified due to a lack of dedicated resources for finance and accounting functions and U.S. GAAP compliance.

Risks

• Inability to generate revenue from product sales and achieve profitability without raising more capital.
• Preclinical development is a long, expensive, and uncertain process, with potential for program termination.
• Limited resources and capital necessitate prioritization of drug candidates, which may prove to be incorrect.
• Difficulties enrolling patients in clinical trials could delay or adversely affect development.
• Clinical drug development is lengthy and expensive, with high failure rates at any stage.
• Limited experience in conducting clinical trials, and earlier results may not be reproduced in future trials.
• Failure of clinical trials to demonstrate safety and efficacy could lead to additional costs, delays, or inability to complete development.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable, potentially delaying or preventing approval.
• Drug candidates may cause undesirable adverse events, limiting approval or resulting in negative consequences post-approval.
• Ongoing regulatory obligations and review post-approval may result in significant expense and penalties for non-compliance.
• Inability to successfully complete the 505(b)(2) pathway for SACT-1 as planned could materially impact FDA approval likelihood.
• Failure to comply with FDA's good manufacturing practice (cGMP) regulations by the company or third-party suppliers could impair marketing or result in FDA enforcement action.
• Even with regulatory approval, drug candidates may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Substantial dependence on the success of the current Lead Projects (ALS-4 and SACT-1).
• Inability to obtain and maintain patent protection for technology and drugs, or if pending patent applications fail to issue.
• Inability to obtain and maintain appropriate scope for patents, allowing competitors to develop similar drugs.
• Inability to protect and enforce intellectual property (IP) rights throughout the world.
• Involvement in lawsuits to protect or enforce IP could be expensive, time-consuming, and unsuccessful.
• Patent rights relating to drug and diagnostics technology candidates could be found invalid or unenforceable if challenged.
• Claims challenging the inventorship of patents and other IP.
• Risk of being sued for infringing IP rights of other parties, leading to costly litigation or delays.
• Unawareness of pending patent applications by others covering similar products.
• Non-compliance with procedural, document submission, and fee payment requirements for patent protection.
• Patent terms may not be sufficient to effectively protect drug and diagnostics technology candidates and business due to long development times.
• Changes in patent law in the United States could diminish the value of patents in general.
• Inability to protect the confidentiality of trade secrets.
• Claims that employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• Inability to execute on the optimal development plan for product candidates if necessary rights are not obtained or maintained through acquisitions or licenses.
• Failure to comply with obligations in IP licensing agreements could lead to monetary damages or loss of license rights.
• Lack of complete control over the preparation, filing, and prosecution of patent applications, or maintenance of patents, licensed from other parties.
• Reliance on unrelated parties to conduct discovery, preclinical studies, and clinical trials.
• Reliance on unrelated parties to manufacture supplies of drug candidates, with risks of insufficient quantities, quality issues, or cGMP non-compliance.
• Delays resulting from the need for additional regulatory approvals due to changes in the manufacturing process of drug candidates.
• Non-compliance with laws regulating the protection of the environment and health and human safety.
• Dependence on retaining the Chief Executive Officer, scientific and clinical advisors, and other key executives and attracting qualified personnel.
• Difficulties in managing organizational growth, especially with a shift to outsourcing key functions.
• Inability to realize the benefits of additional collaborations, strategic alliances, or acquisitions.
• Risk of misconduct or other improper activities by employees, independent contractors, consultants, commercial partners, and vendors.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Failure to establish and maintain proper internal financial reporting controls (material weakness identified).
• Risks of doing business internationally, including unexpected legislative/regulatory changes, economic weakness, and differences in IP protection.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute shareholders, cause debt, or assume contingent liabilities.
• Failure to comply with the U.S. Foreign Corrupt Practices Act (FCPA) or other anti-bribery laws.
• Negative impact on business and results of operations from the UK's withdrawal from the EU (Brexit).
• Product liability lawsuits could incur substantial liabilities and affect the commercialization of drug or diagnostics technology candidates.
• Inadequate insurance coverage to protect against losses.
• Fluctuations in exchange rates could result in foreign currency exchange losses.
• Investments are subject to risks that could result in losses, including cash and cash equivalents.
• Exposure to risks associated with computer hardware, network security, and data storage.
• Business disruptions from supply chain issues, natural disasters, or other events.
• Exposure to various risks related to the regulatory environment of the pharmaceutical industry in the PRC, even without direct operations there.
• Risk of trading prohibition for Class A ordinary shares if the U.S. Public Company Accounting Oversight Board (PCAOB) is unable to inspect auditors for two consecutive years under the Holding Foreign Companies Accountable Act (HFCAA).
• Potential classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes.
• One director (Ian Huen) controls a majority of voting shares (approximately 87%), potentially influencing outcomes against the interests of other shareholders.
• As a controlled company under Nasdaq rules, the company may choose to exempt itself from certain corporate governance requirements.
• May not be able to consolidate the financial results of some affiliated companies (e.g., Libra Sciences Limited).
• The economic substance legislation of the Cayman Islands may adversely impact operations.
• Failure to comply with the continued listing requirements of Nasdaq Capital Market could result in delisting.
• Future sale of a substantial amount of outstanding Class A ordinary shares in the public marketplace could reduce the price.
• Issuances of additional securities could affect ownership and voting rights or dilute shareholders.
• No historical or expected future dividends; any return on investment may be limited to the value of shares.
• Shareholders' rights may be more limited as a Cayman Islands exempted company compared to a company organized in the United States.
• Difficulties for overseas shareholders and/or regulators to conduct investigations or collect evidence within China.
• Ceased to qualify as an emerging growth company, incurring increased costs.
• If the Merger Agreement with DiamiR is not consummated, the company's share price could decline, significant expenses would have been incurred, business opportunities restricted, and the ability to continue current operations limited without additional financing.
• Some Aptorum and DiamiR officers and directors have interests in the Merger that are different from other shareholders.
• DiamiR may not complete the Merger or may be delayed in completing it.
• Covenants in the Merger Agreement impede the ability of Aptorum or DiamiR to make acquisitions or complete other transactions not in the ordinary course of business.
• The lack of a public market for DiamiR shares makes it difficult to evaluate the fairness of the Merger consideration.
• DiamiR has never generated revenue from product sales and may continue to incur significant losses for the foreseeable future.

Future Outlook

The company anticipates submitting INDs for ALS-4 by 2027 and commencing Phase 2 trials shortly thereafter, contingent on securing appropriate collaborative partnerships and adequate funding. It plans further in vivo studies for SACT-1 on other cancer types to maximize its potential. The proposed merger with DiamiR Biosciences is targeted for closing before 2027, and the company will continue to explore other accretive business combination opportunities. R&D expenses are expected to increase significantly with the advancement of drug candidates, and the organization will need to expand its managerial, operational, sales, marketing, and financial personnel.

Management Comments

• "Management will always base its decision on what it believes to be the most efficient use of the Company’s resources to provide the most value to its shareholders."
• "The Company is actively seeking strategic collaborators who can provide both financial support and clinical expertise to advance these therapeutic programs."
• "We intend to seek additional collaborations, strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements in the future, but we may not realize the benefits of these arrangements."
• "We believe our strategy and approach is aligned with the PRC government’s policies, but we cannot ensure that our strategy and approach will continue to be aligned."
• "We intend to keep any future earnings to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future."
• "Our management assessed that the deficiency related to the lack of dedicated resources to take responsibility for the finance and accounting functions and the preparation of financial statements in compliance with generally accepted accounting principles in the United States, or U.S. GAAP, still existed as of December 31, 2025."

Industry Context

StockSavvy.ai notes that Aptorum Group operates in the highly competitive and rapidly changing biopharmaceutical industry, facing larger, more resourced competitors. The company's strategy of focusing on orphan drug designations and drug repurposing (SACT-1) is a common approach to mitigate high R&D costs and risks, as repurposed drugs are estimated to cost significantly less ($300 million vs. $2.6 billion for new drugs) and have higher approval rates (30% vs. new drug applications). The proposed merger with DiamiR Biosciences aligns with a trend of diversification into molecular diagnostics, a growing area for early disease detection and monitoring. However, the substantial doubt about going concern and reliance on external funding are critical challenges in this capital-intensive sector.

Comparison to Industry Standards

• Drug development costs: The filing states the average cost of launching a new drug is estimated to approach US$2.6 billion and can take around 12 years. In contrast, the cost of bringing a repurposed drug is estimated to be around US$300 million. Aptorum's SACT-1 is a repurposed drug, aligning with a lower-cost development strategy compared to de novo drug development.
• Clinical trial success rates: The filing notes that approximately 1 in 1,000 potential drugs graduates to human clinical trials, and nearly 86.2% of drug candidates entering Phase 1 trials fail to achieve drug approval. For repurposed drugs, approval rates are stated to be close to 30%, which is significantly higher than for new drug applications, suggesting SACT-1's approach has a better statistical chance of success.
• Orphan Drug Designation: SACT-1 has received Orphan Drug Designation, which provides benefits like fee reductions, regulatory assistance, and a potential ten-year market exclusivity period in the EU, a common incentive for developing treatments for rare diseases, aligning with industry efforts to address unmet medical needs.
• Internal Control Weakness: The identified material weakness in internal control over financial reporting (lack of dedicated resources for U.S. GAAP compliance) is a significant concern, as robust internal controls are a fundamental expectation for publicly traded companies, especially compared to larger, more established pharmaceutical firms that typically have mature financial reporting infrastructures.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing lawsuit filed on September 3, 2024, by Karen Cheung in the Supreme Court of the State of New York, alleging violations of the federal Racketeer Influenced and Corrupt Organizations Act (RICO), conspiracy to violate RICO, fraud, aiding and abetting breach of fiduciary duty, unjust enrichment, civil conspiracy, and violations of the federal Securities Act of 1933.
• The case was removed to the U.S. District Court for the Southern District of New York on December 27, 2024.
• Plaintiff filed a First Amended Complaint on June 2, 2025.
• The company filed its opening brief on a Motion to Dismiss on July 18, 2025, and believes the claims have no merit, intending to vigorously defend against them.

Related Party Transactions

• Line of Credit with Aeneas Group Limited (an entity controlled by Ian Huen, the CEO) for up to $12,000,000, extended to August 12, 2026, with an interest rate of 8% per annum. The facility remains undrawn.
• Secured convertible note with Jurchen Investment Corporation (wholly owned by Ian Huen) for $3,000,000 principal amount, extended on September 11, 2025, for an additional 12 months, bearing 6% interest per annum and convertible at $2.42 per share. The note is secured by certain shares owned by the Group.
• Loan from Libra Sciences Limited (a related party) with $0.5 million outstanding, for which an allowance for credit loss has been recognized due to its unrecoverable nature.
• CGY Investment Limited (related to former CEO Darren Lui) provided consultancy, advisory, and management services, with fees suspended from August 1, 2023, and the agreement terminated in November 2023.
• ACC Medical Limited provided consultancy, advisory, and management services for clinic operations, with the agreement terminated on June 30, 2023.
• An administrative management services agreement with Libra Sciences Limited was terminated on March 31, 2023.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and significant influence from the controlling shareholder (Ian Huen). The stock price is subject to risks from delisting threats (Nasdaq, HFCAA) and the uncertainty of the DiamiR merger outcome. No dividends are anticipated in the foreseeable future.
• Employees may experience uncertainty about their future roles within the Combined Company following the DiamiR merger. The company's shift to outsourcing key functions introduces dependencies on third-party vendors, potentially affecting job security and internal career progression.
• Customers could benefit from the continued development of therapeutic assets for unmet medical needs (ALS-4, SACT-1) and potential new diagnostic tests resulting from the DiamiR merger.
• Creditors, particularly those holding the secured convertible note with Jurchen Investment Corporation and the line of credit from Aeneas Group Limited, face risks due to the auditor's 'going concern' warning and the company's negative working capital and accumulated deficit.
• Regulatory Bodies will continue to oversee the company's drug development, clinical trials, and financial reporting. The identified material weakness in internal controls requires remediation and ongoing monitoring to ensure compliance.

Next Steps

• Proceeding towards IND submission of ALS-4 for Phase 2 clinical study targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
• Actively seeking strategic collaborators for financial support and clinical expertise to advance ALS-4 Phase 2 and SACT-1 Phase 1/2 trials.
• Anticipates submitting INDs for ALS-4 by 2027 and commencing Phase 2 trials shortly thereafter, contingent on funding.
• Planning to carry out further in vivo studies to study the efficacy of SACT-1 over other types of cancers to maximize its potential.
• Targeting a closing of the DiamiR merger before 2027.
• Will continue to explore other reverse takeover or business combination opportunities that are expected to be accretive to shareholder value.
• Continuing to monitor and assess the implementation and enforcement of PRC cybersecurity and data privacy laws.
• Working to remediate the material weakness in internal control over financial reporting by providing staff training, changing accounting systems, and establishing clear roles and responsibilities.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, as explicitly stated by its independent auditor. This, coupled with negative working capital, a large accumulated deficit, and a material weakness in internal controls, indicates severe financial instability. While the DiamiR merger and R&D pipeline offer potential, the immediate financial risks and dependence on future capital raises make the stock a high-risk investment. A seasoned investor would likely avoid or sell given the fundamental solvency concerns and the significant uncertainties surrounding its future operations and financial viability.

Keywords

Biopharmaceutical, Oncology, Infectious Diseases, Drug Development, Clinical Trials, ALS-4, SACT-1, Neuroblastoma, MRSA, Orphan Drug, FDA, SEC, Nasdaq, Merger, DiamiR Biosciences, Diagnostics, MicroRNA, Patent, Intellectual Property, Going Concern, Capital Raise, Corporate Governance, Cayman Islands, Hong Kong, Financial Reporting